Neuland Laboratories Limited has informed the Exchange regarding 42nd Annual General Meeting Of The Shareholders Of The Company Is Scheduled To Be Held On Tuesday, August 4, 2026'.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2026 results with consolidated revenue growing 37% to ₹2,02,299 lakhs from ₹1,47,684 lakhs in FY2025. Profit after tax rose 40% to ₹36,400 lakhs from ₹26,011 lakhs, driven by robust growth across all geographies — Europe revenue up 57% and USA/North America up 69%. EBITDA margin expanded from ~18% to ~24%. The company recorded an exceptional gain of ₹7,640 lakhs from sale of investment property in Hyderabad. Board recommended final dividend of ₹34 per share (340%). New director Dr. Mauricio Futran appointed. The company approved ₹143.4 crore capacity expansion at Unit 1 (adding 120.5 KL over 12-18 months) citing 91% capacity utilization. Auditors issued unmodified (clean) opinion.
Strong growth trajectory with margin expansion signals operational efficiency gains. The one-time exceptional item boosted bottom line; underlying business shows robust organic growth. Capacity expansion indicates confidence in sustained demand, particularly from US and Europe markets.